When the United States government’s Food and Drug Administration earlier this week called for temporarily halting the giving of Johnson & Johnson’s experimental coronavirus vaccine shots because of the developing of blood clots in people who have received the shots, I asked if we were seeing an example of regulatory favoritism for the new mRNA technology shots over more traditional vaccine shots such as the Johnson & Johnson shots. The question arises because the US government is still encouraging everyone to take experimental mRNA “vaccines” from Moderna and Pfizer-BioNTech regarding which there are also many reports of injury and death.
While a variety or injuries and deaths have been reported after people have taken experimental coronavirus vaccine shots developed respectively by the three companies, if you focus in on just blood clot problems, those problems appear to arise after Moderna and Pfizer-BioNTech experimental coronavirus shots as well as after Johnson & Johnson shots.